featured
Long-Term Efficacy and Safety of Inclisiran in Patients With High Cardiovascular Risk and Elevated LDL-C Levels
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Lancet Diabetes Endocrinol 2023 Jan 05;[EPub Ahead of Print], KK Ray, RPT Troquay, FLJ Visseren, LA Leiter, R Scott Wright, S Vikarunnessa, Z Talloczy, X Zang, P Maheux, A Lesogor, U LandmesserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.